CD8A and neoplasm: Fueled by the development of dedicated, highly specific radiopharmaceuticals in recent years, the non-invasive quantification of tumor infiltration with distinct immune cell subsets, e.g. CD8+ cytotoxic T cells [4], is now rapidly entering clinical practice, providing crucial information for patient selection and on early response to immune checkpoint blockade.